When You Are in a Hurry and Looking for Just the Right Expert Witness to Win Your Case.
800-683-9847

Endocrinology Thyroid Cancer Hormonal Expert Witness

Provides Opinion & Testimony In:

Endocrinology, Diabetes, Hypoglycemia, Thyroid Disease, Cancer, Hormonal Treatments, Testosterone Therapy, Osteoporosis, Adrenal Glands, Neuro-Endocrinology, DUI with Diabetes, Workplace Accommodations, Pharmaceutical Drug, Devise Safety, Medical Big Data, Pharmaco-economics, Obesity, Lipid Treatments, Cardiovascular Treatments

EXPERT 5060

Education

  • 1970 B.A., University of Virginia (Magna Cum Laude)
  • 1974 M.D., University of Maryland

Post Graduate Education and Training

  • 1974-1977 Internship/Residency, Yale-New Haven Hospital & Affiliates, School of Medicine, Medicine PG I, PG II, Pathology
  • 1977-1978 Residency, Georgetown University Hospital, Medicine PG III
  • 1978-1980 Fellowship, Endocrine,The Ohio State University Hospital
  • 1980- 1982 NIH Clinical Associate, National Institute of Aging- Metabolism

Certifications

  • 1975 Board Certified- Internal Medicine, Maryland
  • 1978 Board Certified- Internal Medicine, Ohio
  • 1978 Diplomat, American Board of Internal Medicine
  • 1981 Board Certified- Endocrinology and Metabolism- A.B.I.M.

Medical Licensures

  • 1975 Active Maryland
  • 1978 Inacticve Ohio

Employment History

Academic
Appointments

  • 1980- 1982 Instructor in Medicine, Johns Hopkins University, School of Medicine
  • 1982- 1989 Assistant Professor, University of Maryland, School of Medicine
  • 1989- 1994 Associate Professor, University of Maryland, School of Medicine
  • 2000- 2008 Associate Clinical Professor, Division of Endocrinology, University of Maryland, School of Medicine
  • 2011- present Assistant Professor of Medicine, Johns Hopkins University School of Medicine
  • 8/2017- present Adjunct Associate Professor, University of Maryland, School of Medicine

Professional Society Membership

  • 1994- 1996 General Member, American Medical Association
  • 1994- 2000 General Member, The Endocrine Society
  • 1994- present Professional Section Member, Complications Committee, American Diabetes Association
  • 2008- present General Member, Americian Association of Clinical Endocrinologists
  • 2009- 2010 General Member, American Federation for Clinical Research
  • 2010- 2017 Executive Committee, Johns Hopkins Clinical Research Network, Johns Hopkins Medical Institution

Clinical Activities

Clinical
Expertise

  • Board Certified Endocrinologist
  • Additional board certification in the sub specialty of endocrinology and metabolism Research focus in the area of endocrinology and metabolism

Institutional Service

  • 2014- present Chairman, Greater Baltimore Medical Center Institutional Review Board

Local and National Service

  • 2009- present Consultant, Endocrine and Diabetes

Teaching Service

1982- 1985 Consultant Attending
Division of Endocrinology- Department of Medicine
University of Maryland School of Medicine
2000- 2008 Medical House Staff Attending Rounds

Teaching Conferences
Mercy Hospital
2009- present Medical House Staff Noon

Teaching
Greater Baltimore Medical Conference Center

Grant Support

  • Active Grants
  • 2004- present TrialNet Natural History Study of the Development of Type 1 Diabetes,
    NIH
  • 2012- present A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease (Randomized EValuation of the Effects of Anacetrapib through Lipid-modification) , CTSUREVEAL1 ; HPS 3/ TIMI 55: REVEAL
    Merck
  • 2014- present Co- Investigator: A Case – Finding Approach to Screening for Monogenic Diabetes, National Human Genome Research Institute (NHGRI),
    NIH, Principal Investigator: Toni Pollin, MS, PhD
  • 2014- present A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment with BELVIQ (lorcaserin HCI) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors APD356-G000-401
    Eisai
  • 2015- present PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Natural History Registry for Patients with Chronic Hypoparathyroidism, PAR-R13-001
    NPS Pharmaceuticals, Inc.
  • 2016- present Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk Open Label Extension, Fourier OLE Study
    Amgen
  • 2016- present Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment, NN9924-4234 (PIONEER)
    Novo Nordisk
  • 2016- present Getting to an imprOved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia management (GOULD): a Registry of High Cardiovascular Risk Subjects in the United States
    Amgen
  • 2017- present A randomized, double-blind, placebo-controlled, event
    driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP, Open Label Extension CACZ885M2301 Novartis
  • 2017- present Efficacy and Safety of Semaglutide once weekly versus placebo as add-on to SGLT-2i in subjects with type 2 diabetes mellitus, NN9535-4269
    Novo Nordisk
  • 2017- present A digital health tool for insulin titration (DHIT) for individuals with type 2 diabetes: a prospective outcomes study with a retrospective control group isage Rx, Inc.
  • 2017- present A randomized, double-blind, dose finding study to evaluate the change in weight after 24 weeks treatment with 8 doses of LIK066 compared to placebo in obese or overweight adults, followed by 24 weeks treatment with 2 doses of LIK066 and placebo, CLIK066
    Novartis
  • 2018- present Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients, Mannkind
  • 2018- present A Randomized, Multi-center, Double-Blind, Parallel-Group Clinical Study Comparing the Efficacy and Safety of MYL-1501D Produced by 2 Manufacturing Processes in Type 1 Diabetes Mellitus Patients, Mylan

Completed Grants

  • 1983-1985
    • Glipizide Sulfonylurea, Phase II Trial
      Pfizer Pharmaceuticals
  • 1986- 1993
    • Diabetes Control and Complications Trial NIH
  • 1997- 2002
    • Osteoporosis Studies on Ibandronate
      Roche Pharmaceuticals
  • 1997- 2003
    • Evista Studies
      Eli Lilly Pharmaceuticals
  • 1999
    • Diabetes Control and Lipids Study Parke-Davis
  • 2000- 2005
    • Insulin Lispro Low Mixture Plus Metformin Compared to NPH Insulin Plus Metformin in Subjects with Type 2 Diabetes
      Eli Lilly
    • Rosiglitazone Monotherapy compared to Metformin or Glyburide in Type 2 Diabetics
      Glaxo SmithKline
    • Pioglitizone vs. Rosiglitazone in Type 2 Diabetics Eli Lilly
    • Omapatrilat Cardiovascular Treatment Assessment vs. Enalipril Bristol-Myers Squibb
    • Synthetic 10-Component Conjugated Estrogen vs. Placebo for Prevention of Osteoporosis in Hysterectomized, Postmenopausal Women
      Endeavor Pharmaceuticals
    • Oral Insulin Spray studies Generex Pharmaceuticals
    • Sub Investigator: Comparing effects of Carvedilil and Metoprolol on Glycemic Control in Hypertensive and Type II Diabetes Mellitus Patients, Principal Investigator: James H. Mersey, MD
      SmithKline Beecham
    • Comparing Celecoxib, Rofecoxib and Naproxen in Hypertensive Patients with Osteoarthritis and Type II Diabetes Mellitus
      Pharmacia
    • Placebo Controlled Dose Finding Study of KAD-1229 in Type II Diabetic Patients
      Kissei Pharmaceuticals
    • Sub Investigator: Open Label Trial to Assess Noninferiority Between Pre and Post-meal Administration of CMR 1964 and Pre-meal Regular Human Insulin in Type I Diabetes Mellitus Patients Receiving Insulin Glargine as the Basal Insulin therapy, Principal Investigator: James H. Mersey, MD
      Aventis Pharmaceuticals,
    • Sub Investigator: The Impact of Medical Subspecialty on Patients Compliance to Treatment, Principal Investigator: James H. Mersey, MD Kos/Dupont Pharmaceuticals
    • Sub Investigator: Comparing HMR 1964 with Regular Human Insulin Injected Subcutaneously in Subjects with Type 2 Diabetes Mellitus Also Using NPH Insulin, and Which Will Lead into a Comparative 26 Week Safety Extension Study, Principal Investigator: James H. Mersey, MD
      Aventis Pharmaceuticals
    • Sub Investigator A Randomized, Double- Blind, Dose Ranging, Dose Comparison- Controlled Trial to Determine the Safety and Efficacy of BMS- 298585 in Subjects with Type 2 Diabetes, Principal Investigator: James H. Mersey, MD
      Bristol-Myers Squibb
    • Sub Investigator: The Safety and Efficacy of Omapatrilat Modified Release Formulation in Subjects with Mild to Moderate Hypertension, Principal Investigator: James H. Mersey, MD
      Bristol-Myers Squibb
    • Sub Investigator: Evaluation of Diabetic Retinopathy Progression in Subjects with Type 2 Diabetes Mellitus Treated with Insulin,
      Principal Investigator: James H. Mersey, MD Aventis Pharmaceuticals
    • Sub Investigator: Simvastatin and Fenofibrate Efficacy Trial, Principal Investigator: James H. Mersey, MD
      Merck and Co
    • Sub Investigator: A Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events and a parallel study, Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease, Principal Investigator: James H. Mersey, MD
      Boehringer Ingelheim
    • Evaluating the Efficacy and Safety of Tolterodine versus Placebo in the Treatment of Urinary Urgency and Frequency
      Pharmacia
    • Comparing 3 Doses of Conjugated Estrogens with Placebo in Hysterectomized Postmenopausal Women for the Prevention Of Osteoporosis
      Endeavor Pharmaceuticals
    • Comparing a Stratified Care Treatment Regimen versus Standard Therapy for the Acute Treatment of Migraine Headaches
      Astra Zeneca
    • Sub Investigator: Comparing the Effects of Lotrel to Amlodipine and Benazepril on Systolic Blood Pressure and Pulse Pressure in Patients with Systolic Hypertension, Principal Investigator: James H. Mersey, MD Novartis Pharmaceuticals
    • Sub Investigator: Correction of Hemoglobin and Outcomes in Renal Insufficiency, Principal Investigator: James H. Mersey, MD
      Ortho Biotech
    • Improvement of Brittle Diabetes Control After Switching to Insulin Glargine from NPH Insulin: A Continuous Glucose Monitoring System
      Aventis
    • The Effect of LY333531 on Albuminuria in Patients with Type 2 Diabetes Eli Lilly and Company
    • Treatment of Peripheral Neuropathy in Patients with Diabetes: A Phase 3 Pivotal Clinical Trial
      Eli Lilly and Company
    • Treatment for Symptomatic Peripheral Neuropathy in Patients with Diabetes
      Eli Lilly and Company
    • A Double-blind, Multi-center, Randomized, Placebo-controlled, Parallel Group Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients with Mild to Moderate Hypertension
      Bertek
    • A Multi-center, Parallel Group Extension Study to Determine the Safety and Efficacy of Long-Term Nebivolol Exposure in Patients with Mild to Moderate Hypertension
      Bertek
    • A Double-blind, Multi-center, Randomized, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients with Mild to Moderate Hypertension Bertek
    • A Multi-center, Randomized, Double-blind, Double-dummy Study Evaluating the Safety and Efficacy of the Addition of Amlodipine to Quinapril or Losartan in the Treatment of Diabetic Hypertensive Subjects
      Pfizer
    • A One Year, Open, Randomized, Parallel, Three-Arm Study Comparing Exubera vs. Avandia as Add on Therapy vs, Exubera Substitution of Sulfonylurea in Patients with Type 2 Diabetes, Poorly Controlled on Combination Sulfonylurea and Metformin Treatment
      Pfizer
    • A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Dose-Range Finding Study of Once Daily Dosing of L-000224715 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
      Merck
    • Assessment of Biomarkers in Diabetes Hoffmann-La Roche
    • A Phase 3B, Multi-Center, Open Label Study Investigating the Clinical Utility and Safety of Pramintide in Subjects with Type 1 and Type 2 DiabetesMellitus Who Have Not Achieved Glycemic Targets with Insulin Therapy
      Amylin
    • The Global Hypopituitary Control and Complications Study (HypoCCS) Lilly
    • APIDRA Administered in a Fixed Bolus Regimen vs. a Variable Bolus Regimen Based on Carbohydrate Counting in Adult Subjects with Type 2 Diabetes Receiving Lantus as Basal Insulin: A Multicenter, Randomized, Parallel Open Label Clinical Study
      Aventis
    • Effects of Arzoxifene on Vertebral Fracture Incidence and on Invasive Breast Cancer Incidence in Postmenopausal Women with Osteoporosis or with Low Bone Density
      Lilly
    • Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group Evaluation of the Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily Compared with Atorvastatin Alone, on the Occurrence of Major Cardiovascular Events in Subjects with Coronary Heart Disease or Risk Equivalents
      Pfizer
    • 3S Confidence Glucose Monitoring System Alternate Site (Forearm) Capillary Evaluation
      Roche

      TrialNet Natural History Study of the Development of Type 1 Diabetes, NIH Baltimore-Washington Major Affiliate
      NIH

  • 2006
    • Type 1 Diabetes Genetics Consortium NIH, NIDDK, JDRF
    • A Prospective Randomized Trial Of The Cost Effectiveness Of Lantus Plus Apidra Compared To Premix Analog Insulin Regimens In Patients With Type 2 Diabetes (Lace)
      sanofi aventis
    • Pulmonary Outcomes within a 2 Year Period in Subjects with Diabetes Mellitus Treated with Technosphere Insulin or Usual Antidiabetic Treatment, Mannkind
    • A Double-Blind, Multi-Center, International (US and Europe), Randomized, Placebo-Controlled Study of Safety and Efficacy of Trospium Chloride 60 Mg Modified Release Capsules Versus Placebo, Once Daily, For 12 Weeks Followed By a 9-Month, Open-Label Treatment Phase In Patients With Overactive Bladder
      Indevus
    • The Durability of Twice-Daily Insulin Lispro Low Mixture Compared to Once- Daily Insulin Glargine when added to Existing Oral Therapy in Patients with Type 2 Diabetes and Inadequate Glycemic Control
      Lilly
    • Effects of NovoLogC› Mix 70/30 (biphasic insulin aspart 70/30) BID and QD vs. Byetta TM (exenatide) BID on Glycemic Control: A Multicenter, 24-Week,
      Open-Label, Parallel Group Study in Patients with Type 2 Diabetes Mellitus not Achieving Glycemic Targets with Metformin and a Sulfonylurea
      Novo Nordisk
    • A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multi-Center Study to Examine Safety and Establish Proof of Concept with PHX1149 in Patients with Type 2 Diabetes Mellitus
      Phenomix
    • A Phase 3, Open-Label, Parallel-Group Study to Evaluate the Efficacy of Preprandial Human Insulin Inhalation Powder (HIIP) Compared to Preprandial Injectable Insulin in Patients with Type 1 Diabetes Mellitus
      Lilly
    • GOLD (ACCU-CHEKO Performa) Glucose Monitoring System Alternate Site Capillary Evaluation
      Roche
    • A Phase 3, Open-Label, Three-Group Parallel Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) in Patients with Type 2 Diabetes Treated with Once-Daily Insulin Glargine
      Lilly
    • Lipid Treatment Assessment Project Pfizer
    • A 2-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Long-Term Efficacy And Safety Of CP-945,598 In The Treatment Of Obese Subjects
      Pfizer
    • A 1-Year, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Efficacy And Safety Of CP-945,598 In The Treatment Of Overweight, Oral Agent-Treated Subjects With Type 2 Diabetes Mellitus, Pfizer
  • 2007
    • A study to compare Exubera inhaled insulin with injectable insulin Pfizer
    • A Prospective, Randomized, Naturalistic Study Using Insulin Glargine or Detemir to Treat Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Medications Alone
      sanofi aventis
    • An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAJECT and Regular Human Insulin in Patients with Type 1 Diabetes Mellitus
      Biodel
    • Correlation Between the TCF7L2 Test and Diabetes Drug Response in Type 2 Diabetics
      deCode Genetics
  • 2008
    • A Double-Blind, Randomized, Placebo-Controlled, 5-Arm Titration Study to Evaluate the Efficacy and Safety of TAK-491 When Compared With Valsartan and Olmesartan in Subjects With Essential Hypertension
      Takeda
    • A multi-centre, randomised, open-label, cross-over study to explore effectiveness, safety and preference of a new disposable pen PDS290 vs. FlexPeno in subjects with type 1 or type 2 diabetes
      Novo Nordisk
    • Freedom 9 mm (ACCU-CHEK% Aviva) Glucose Monitoring System Alternative Site Capillary Evaluation
      Roche

      Freedom 7mm (ACCU-CHEKO Performa) Glucose Monitoring System Patient vs Techncian Capillary Evaluation
      Roche

    • A Multicenter, Randomized, Placebo-Controlled, “Factorial” Design, 12-Month Study To Evaluate The Efficacy And Safety Of AVE5530 25 Mg/Day And 50 Mg/Day Co-Administered With All Registered Atorvastatin Strengths Ranging From 10 Mg To 80 Mg In Patients With Primary Hypercholesterolemia
      sanofi aventis
    • A 12-Week, Double-Blind, Placebo-Controlled Trial of LY2428757 in Patients with Type 2 Diabetes Mellitus
      Eli Lilly
    • The Effect Of Insulin Detemir In Combination With Liraglutide And Metformin Compared To Liraglutide And Metformin In Subjects With Type 2 Diabetes. A 26-Week, Randomised, Open-Label, Parallel-Group, Multicentre, Multinational Trial With A 26-Week Extension
      Novo Nordisk
    • A Retrospective Clinical Practice Evaluation Of Lantus Cost Effectiveness Compared To Levemir In Diabetes Patients ( Lace 2 Pilot Study ) sanofi aventis
  • 2009
    • LACE EMR Multi-Site Study – A Retrospective Clinical Practice Evaluation Of Lantus Cost-Effectiveness Compared To Levemir In Insulin-Naive Type 2 Diabetes Patients (Insulin Naive EMR Study)
      sanofi aventis
      A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Dutogliptin in Patients with Type 2 Diabetes Mellitus on Background Treatment with Glimepiride with or without Metformin
      Forest Research
    • A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Dutogliptin in Patients with Type 2 Diabetes Mellitus on Background Treatment with Pioglitazone
      Forest Research
    • Glycemic Effects Of Nebivolol Compared With Metoprolol Extended Release And Compared With Hydrochlorothiazide In Hypertensive Patients With Type 2 Diabetes Mellitus: A Pilot Study, NEB-MD-19
      Forest Research
    • A Trial Comparing Efficacy And Safety Of NN5401 With Insulin Glargine, Both In Combination With Oral Antidiabetic Drugs In Subjects With Type 2 Diabetes – NN5401-3593
      Novo Nordisk
    • Accu-Chek Aviva Glucose Monitoring System Alternative Site Capillary Evaluation Patient vs. Technician, D8026-09-32
      Roche
    • A Phase 2 Study of LY2605541 Compared with Insulin Glargine in the Treatment of Type 2 Diabetes Mellitus – I2R-MC-BIAC
      Eli Lilly
    • A Phase 2 Study of LY2605541 Compared with Insulin Glargine in the Treatment of Type 1 Diabetes Mellitus – 12R-MC-BIAD
      Eli Lilly
    • A 26-Week, Randomised, Controlled, Open Label, Multicentre, Multinational, Three-Arm, Parallel, Treat-To-Target Trial Comparing Efficacy And Safety Of Two Different Dosing Regimens Of SIBA And One Dosing Regimen Of InsulinGlargine, Both In Combination With Meal-Time Insulin Aspart In Subjects With Type 1 Diabetes Mellitus – NN1250-3770
      Novo Nordisk
  • 2010
    • A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study To Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide In Type 2 Diabetic Patients After An Acute Coronary Syndrome – EFC11319
      sanofi aventis
    • Sub Investigator: Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study To Evaluate The Effect Of 5 Mg Or 20 Mg Nebivolol Once Daily On Blood Pressure N Patients With Systolic Stage 2 Hypertension, NEB-MD- 20, Principal Investigator: James H. Mersey, MD
      Forest Research
    • A Randomized, Double-Blind, Parallel-Group Study To Evaluate The Effects Of First Line Treatment With A Free Combination Of Nebivolol And Lisinopril Compared With Placebo And The Monotherapy Components On Blood Pressure In Patients With Stage 2 Diastolic Hypertension, NEB-MD-25 Forest Research
    • Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events
      Novo Nordisk
    • Protocol #: D8026-10-17 Freedom II 7 mm (ACCU-CHEKC› Performa) Test Strip with the ACCU-CHEKO Performa Glucose Monitoring System (Alternative Site Capillary Evaluation)
      Roche Diagnostics
    • 2011 An open label randomized multicenter study to assess patient preference for and evaluate clinical benefit of insulin glargine (Lantuso) SoIoSTARO pen versus conventional vial/syringe method of insulin glargine (Lantuso) injection therapy in patients with type 2 diabetes mellitus, Lantu L 05191
      sanofi aventis
  • 2012
    • Effectiveness of V-Go TM for Patients with Diabetes in a Real-world Setting: A Long-term, Prospective, Observational Registry (SIMPLE) Study, V4006 Valeritas
    • A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Safety and Insulin-Sparing Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Alone or in Combination With Metformin, MK- 0431, Protocol 260
      Merck
    • A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy In Patients with Clinically Evident Cardiovascular Disease, AMG 145 20110118
      Amgen
    • Glycemia in Diabetic Elders (GLiDE) Trial Johns Hopkins Clinical Research Network
  • 2013
    • Protocol D01792.01-12-07 ACCU-CHEN Aviva (No Code) Glucose Monitoring System with the ACCU-CHEK” Aviva Plus Test Strip ISO 15197 Section 8 User Performance Evaluation
      Roche
    • Protocol D01792.01-12-08 ACCU-CHEK” Aviva (No Code) Glucose Monitoring System with the ACCU-CHEK” Aviva Plus Test Strip Alternative Site Capillary Evaluation
      Roche
    • Sub Investigator: A Phase III Clinical Trial to Study the Safety and Efficacy of K-1293 Compared to Lantus TM in Subjects with Type 1 Diabetes Mellitus
      Principal Investigator: James H. Mersey, MD Merck, Sharp and Dohme Corporation
    • Efficacy and Safety of FIAsp compared to insulin aspart both in Combination with insulin detemir in Adults with Type 1 Diabetes Onset” 1
      Novo Nordisk
  • 2014
    • A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR (LIGHT Study)
      Parexel Orexigen
    • A randomized, double-blind, placebo-controlled, event driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP, CACZ885M2301
      Novartis
    • A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment with BELVIQ (lorcaserin HCI) of the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors APD356- G000-401, Eisai
    • NIH: A Case – Finding Approach to Screening for Monogenic Diabetes, National Human Genome Research Institute (NHGRI), Co- Investigator
  • 2015
    • LX4211-309: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients with Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control with Insulin Therapy, Lexicon
    • BI1245.72: A Phase III, randomised, double blind, placebo-controlled, parallel group, efficacy, safety and tolerability trial of once daily, oral doses of Empagliflozin as Adjunctive to insulin thErapy over 26 weeks in patients with Type 1 Diabetes Mellitus (EASE-3), Boehringer Ingelheim
    • NN1218-4131: Efficacy and Safety of Faster-acting Insulin Aspart compared to NovoRapido both in combination with Insulin Degludec in Adults with Type 1 Diabetes, Novo Nordisk
Groups